ClinicalRM and Mapp Biopharmaceutical Combine Efforts to Continue the Fight against Ebola

Posted on August 12, 2016 · 2 min read

ClinicalRM and Mapp Biopharmaceutical Combine Efforts to Continue the Fight against Ebola - Featured Image | MEA Markets
Share this article
Image

ClinicalRM and Mapp Biopharmaceutical Combine Efforts to Continue the Fight against Ebola

ClinicalRM will again deploy its boots-on-the-ground approach to fighting Ebola Virus Disease (EVD) with an expanded access protocol for ZMappTM, an investigational treatment for EVD, in Africa and the U.S.

ClinicalRM will perform as subcontractor under federally funded Contract No. HHSO100201600021C, awarded to Mapp Biopharmaceutical Inc. (Mapp) by the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, to assist in carrying out an expanded access protocol for ZMappTM, a cocktail of three monoclonal antibodies being developed by Mapp/LeafBio to treat EVD.

This award is the latest instance of government and industry calling for ClinicalRM’s expertise in combating global health crises. The ZMappTM protocol will take place in some of the historically hardest-hit areas for EVD ‘ Sierra Leone, Liberia and Guinea ‘ as well as at least three sites in the U.S. ClinicalRM’s tasks include training staff at study sites, monitoring the safety of study participants and managing the safe storage and shipping of the experimental product, particularly during periods when there are no EVD-positive patients. ClinicalRM’s Global Infrastructure Development (GID) group will ensure the capabilities of the African sites to perform the work and may make necessary infrastructure, laboratory, technology and operational improvements. The study may require ClinicalRM to mobilize rapid-response treatment units, working in the field to administer ZMappTM to patients in situations where EVD cases occur in remote areas.

‘Our involvement in this study is an acknowledgement of the expertise we gained during the 2014 outbreak working with EVD and the research environment in West Africa,’ ClinicalRM President Joseph Sgherza said. ‘Our GID group’s motto ‘ and goal ‘ is ‘Leave Something Behind.’ We didn’t simply bring in bloodmobiles and staff as a temporary fix until the crisis was over ‘ we stayed to build a sustainable structure of labs, supply chains, communications systems and highly trained clinicians that can now support research projects from sponsors around the world.’

As therapeutic options for EVD are extremely limited, potent agents to treat patients with EVD are needed. Of the experimental agents that have demonstrated survival benefit in non-human primate models, ZMappTM is one of the most promising therapeutic interventions developed to date.

 

You might also like

Looking for more? Gain deeper insights with these recommended articles, selected to provide further value.

March 20, 2024 Red Sea Crisis Offers Glimpse Into Future Of Managing Global Supply Chains

Ongoing tension in the Red Sea is yet another geopolitical crisis that has upended the international supply chain in recent years, shining a spotlight on its frailty during times of volatility on the global stage.

March 19, 2021 Saudi Industrial Development Fund Approves USD 4.5 Billion in Projects for the First Time In Its History

The Saudi Industrial Development Fund (SIDF), Saudi Arabia's main financial enabler for its industrial transformation, has approved 212 loans that amounted to USD 4.5 billion in 2020 for 201 companies in the fields of industry, mining, energy...

December 2, 2019 Dubai-based Fintech, Beehive, Releases State of the SME Ecosystem Report

Beehive, MENA's first regulated peer to peer lending platform, has released an insightful new report revealing the state of MENA's SME ecosystem.

Join our newsletter.

Gain Access To Exclusive Content

Stay Updated With The Latest News

It's Free To Subscribe

By signing up, you agree to receive marketing emails.

Join our newsletter box - side image
Trusted by the best teams around the world